Thesis
Niyad's PMA submission hinges on completing the 70-patient NEPHRO CRRT study; BTD status supports a streamlined path if data hold
Niyad is a regional citrate anticoagulation device targeting extracorporeal circuit anticoagulation in critically ill patients undergoing CRRT. The thesis resolves on whether the completed NEPHRO CRRT registrational study generates sufficient safety and efficacy data to support PMA approval. The primary risk is that heparin and citrate-based anticoagulation protocols are already embedded in ICU practice, and established CRRT platforms from Baxter and Fresenius limit commercial displacement even with approval.
Focus
Niyad PMA Submission to FDA
2026
Bull
If NEPHRO CRRT completes enrollment and delivers data showing Niyad maintains circuit patency with a favorable bleeding profile versus systemic heparin anticoagulation in CRRT patients, the PMA submission proceeds on schedule with BTD support. A successful submission, followed by FDA acceptance and potential accelerated review, would validate the registrational strategy and position Niyad as the first purpose-built regional anticoagulant device approved for CRRT, unlocking commercialization in a large and underserved ICU population.
Bear
The most likely failure modes are insufficient efficacy signal — particularly if circuit life or filter patency data fall below the performance threshold required to support the primary endpoint — or an unacceptable safety profile driven by systemic heparin-like bleeding events that undermine the regional anticoagulation premise. A slower-than-projected enrollment tail could also delay study completion and push the submission beyond current guidance, extending cash burn against a balance sheet that, at $20.4M year-end 2025, has limited runway for prolonged delays.
Unlock the full thesis for TLPH.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialGenerated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.